D-0075-2022 Class III Terminated

Recalled by Ultra Seal Corporation — New Paltz, NY

FDA drug recall D-0075-2022 was initiated by Ultra Seal Corporation on Oct 13, 2021 and is designated Class III. Reason for recall: Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compound Salicylic Acid. The recall status is terminated (terminated Mar 28, 2022). Affected quantity: 991,310 tablets.

Recall details

Product Type
Drugs
Report Date
Nov 3, 2021
Initiation Date
Oct 13, 2021
Termination Date
Mar 28, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
991,310 tablets

Product description

Advance Formula Pain Reliever (Acetaminophen 250 mg/Aspirin 250 mg/Caffeine 65 mg) tablets, 2 tablets Per Packet, Packaged in 12,000 Packets/Case, PO# 007564-00, Item# 1170, Mfg. for: Advanced First Aid, Baltimore, MD 21237; American Safety & First Aid, Osceola, IN 46561 (Shipping Label)

Reason for recall

Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compound Salicylic Acid.

Distribution pattern

Nationwide in the USA.

Code information

Lot #: AK-9457, exp. date 22-Jan; AK-9521, exp. date 22-Mar; AK-9959, exp. date 22-Dec; AK-1017, exp. date 23-Jan

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0075-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0075-2022. Report a data issue: hello@regdatalab.com.